Explore

Trendline Trendline
FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Timeline

FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Timeline

FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Timeline
Trendline Trendline
Daiichi Sankyo Announces Ambitious Five-Year Plan for Oncology Leadership

Daiichi Sankyo Announces Ambitious Five-Year Plan for Oncology Leadership

Daiichi Sankyo Announces Ambitious Five-Year Plan for Oncology Leadership
Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives
Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amid Expanding RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amid Expanding RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amid Expanding RNAi Therapeutics
Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Q2 2026 Financial Results

Arrowhead Pharmaceuticals Reports Strong Q2 2026 Financial Results

Arrowhead Pharmaceuticals Reports Strong Q2 2026 Financial Results
Trendline Trendline
Regeneron Receives FDA Approval for First Neurosensory Gene Therapy, Otarmeni

Regeneron Receives FDA Approval for First Neurosensory Gene Therapy, Otarmeni

Regeneron Receives FDA Approval for First Neurosensory Gene Therapy, Otarmeni
Trendline Trendline
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Trendline Trendline
Altasciences and Certara Partner to Enhance Early Drug Development with Model-Informed Approaches

Altasciences and Certara Partner to Enhance Early Drug Development with Model-Informed Approaches

Altasciences and Certara Partner to Enhance Early Drug Development with Model-Informed Approaches
Trendline Trendline
AN2 Therapeutics to Present at 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Present at 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Present at 2026 Stifel Virtual Targeted Oncology Forum
Trendline Trendline
Rocket Pharmaceuticals Reports Financial Results and Progress in Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Progress in Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Progress in Gene Therapy Pipeline
Trendline Trendline
Rocket Pharmaceuticals Advances Gene Therapy Pipeline with FDA Engagement and Financial Strength

Rocket Pharmaceuticals Advances Gene Therapy Pipeline with FDA Engagement and Financial Strength

Rocket Pharmaceuticals Advances Gene Therapy Pipeline with FDA Engagement and Financial Strength
Trendline Trendline
Ascendis Pharma Shifts Focus Back to Rare Endocrinology Amid Cancer Setbacks

Ascendis Pharma Shifts Focus Back to Rare Endocrinology Amid Cancer Setbacks

Ascendis Pharma Shifts Focus Back to Rare Endocrinology Amid Cancer Setbacks